Health
Novel treatment avenue for resistant cancers: Removing SORLA protein from drug-resistant HER2-positive cancer cell lines – Medical Xpress
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska’s research group…
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska’s research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitized anti-HER2 resistant breast cancer brain metastasis to targeted therapy.
HER2…
-
Business15 hours ago2 must-have ASX shares to buy for dividend income investors
-
Noosa News17 hours agoUniversity of Queensland researchers survey population of endangered White’s Seahorse
-
General16 hours agoMontana’s house was gutted by an accidental fire. Then her landlord accused her of starting it
-
Business16 hours agoThe smartest ASX dividend stocks to buy with $5,000 right now